BioCentury | Mar 1, 2021
Deals

With Phase III started in head and neck cancer, Debiopharm partners lead program with Germany’s Merck

...By Paul Bonanos, Associate Editor Debiopharm will bank €188 million ($226.6 million) for pipeline development now...
...Phase II trial (HR=0.49; p=0.0261). The treatment has breakthrough therapy designation from FDA.Beyond the upfront payment, Debiopharm Group...
...medullary thyroid cancer; and its WEE1 inhibitor Debio 0123 is in Phase I for solid tumors.Debiopharm’s...
BioCentury | Jul 9, 2020
Finance

July 8 Quick Takes: CapitalBio raises $113M, plans Shanghai IPO; plus Aidea, CF PharmTech, Denovo, Nucleai and Vaxdyn

...Nucleai raised $6.5 million in an initial close of a series A round led by Debiopharm's...
BioCentury | May 26, 2020
Distillery Therapeutics

Blocking inhibitor of apoptosis proteins in liver cells to treat malaria

...has birinapant in Phase I testing for solid tumors. Ascentage Pharma Group International (HKEX:6855) and Debiopharm Group...
BioCentury | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

...AstraZeneca’s AZD1775 is in Phase II testing for ovarian cancer and other solid tumors, and Debiopharm Group...
BioCentury | Jan 18, 2019
Product Development

ImmunoGen’s milestone year

...longer focused, including B cell malignancies. In May 2017, ImmunoGen off-loaded its IMGN529 program to Debiopharm Group...
...American Society of Hematology (ASH), Washington, D.C. CytomX Therapeutics Inc. (NASDAQ:CTMX), South San Francisco, Calif. Debiopharm Group...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

...study of betalutin is a Phase II trial in lymphoma. NNV003 is in preclinical development. Debiopharm Group...
...ImmunoGen Inc. last year. The compound is in Phase II trials for DLBCL and NHL. Debiopharm’s...
...Hematology (ASH), Washington D.C. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Boehringer Ingelheim GmbH, Ingelheim, Germany Debiopharm Group...
BioCentury | Jul 10, 2018
Company News

Management tracks: G1, Collegium, Nimbus

...as CMO. He was head of clinical R&D at the Debiopharm International S.A. unit of Debiopharm Group...
BioCentury | May 10, 2018
Emerging Company Profile

Abac’s precision platform

...Corporate partners: None Number of employees: 4 Funds raised: €16 million Investors: Caixa Capital Risc, Debiopharm...
BioCentury | Feb 16, 2018
Finance

Quark gets specific

...on Feb. 15. Fellow new investors GF Securities Co. Ltd. (SZSE:00076; HKSE:1776), Caixa Capital Risc, Debiopharm...
BioCentury | Feb 16, 2018
Financial News

Abac raises €16M series A

...A round led by Pontifax. New investors Global Health Science Fund, Caixa Capital Risc and Debiopharm...
...multi-drug resistant Acinetobacter baumannii . Pontifax's Silvia Noiman, Quark Venture's Zafrira Avnur, Caixa's Carlos Esteban, Debiopharm's...
Items per page:
1 - 10 of 272
BioCentury | Mar 1, 2021
Deals

With Phase III started in head and neck cancer, Debiopharm partners lead program with Germany’s Merck

...By Paul Bonanos, Associate Editor Debiopharm will bank €188 million ($226.6 million) for pipeline development now...
...Phase II trial (HR=0.49; p=0.0261). The treatment has breakthrough therapy designation from FDA.Beyond the upfront payment, Debiopharm Group...
...medullary thyroid cancer; and its WEE1 inhibitor Debio 0123 is in Phase I for solid tumors.Debiopharm’s...
BioCentury | Jul 9, 2020
Finance

July 8 Quick Takes: CapitalBio raises $113M, plans Shanghai IPO; plus Aidea, CF PharmTech, Denovo, Nucleai and Vaxdyn

...Nucleai raised $6.5 million in an initial close of a series A round led by Debiopharm's...
BioCentury | May 26, 2020
Distillery Therapeutics

Blocking inhibitor of apoptosis proteins in liver cells to treat malaria

...has birinapant in Phase I testing for solid tumors. Ascentage Pharma Group International (HKEX:6855) and Debiopharm Group...
BioCentury | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

...AstraZeneca’s AZD1775 is in Phase II testing for ovarian cancer and other solid tumors, and Debiopharm Group...
BioCentury | Jan 18, 2019
Product Development

ImmunoGen’s milestone year

...longer focused, including B cell malignancies. In May 2017, ImmunoGen off-loaded its IMGN529 program to Debiopharm Group...
...American Society of Hematology (ASH), Washington, D.C. CytomX Therapeutics Inc. (NASDAQ:CTMX), South San Francisco, Calif. Debiopharm Group...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

...study of betalutin is a Phase II trial in lymphoma. NNV003 is in preclinical development. Debiopharm Group...
...ImmunoGen Inc. last year. The compound is in Phase II trials for DLBCL and NHL. Debiopharm’s...
...Hematology (ASH), Washington D.C. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Boehringer Ingelheim GmbH, Ingelheim, Germany Debiopharm Group...
BioCentury | Jul 10, 2018
Company News

Management tracks: G1, Collegium, Nimbus

...as CMO. He was head of clinical R&D at the Debiopharm International S.A. unit of Debiopharm Group...
BioCentury | May 10, 2018
Emerging Company Profile

Abac’s precision platform

...Corporate partners: None Number of employees: 4 Funds raised: €16 million Investors: Caixa Capital Risc, Debiopharm...
BioCentury | Feb 16, 2018
Finance

Quark gets specific

...on Feb. 15. Fellow new investors GF Securities Co. Ltd. (SZSE:00076; HKSE:1776), Caixa Capital Risc, Debiopharm...
BioCentury | Feb 16, 2018
Financial News

Abac raises €16M series A

...A round led by Pontifax. New investors Global Health Science Fund, Caixa Capital Risc and Debiopharm...
...multi-drug resistant Acinetobacter baumannii . Pontifax's Silvia Noiman, Quark Venture's Zafrira Avnur, Caixa's Carlos Esteban, Debiopharm's...
Items per page:
1 - 10 of 272